Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

LYON, France February 23, 2009 Flamel Technologies S.A. (Nasdaq: FLML) today announced that

Jeffery Vick has joined its senior management team as Flamel s Chief Business Officer. Mr. Vick

previously served as Chief Executive Officer of Silence Therapeutics plc, a leading European RNAi

company. Mr. Vick received his MBA from Stanford University, his MS in Chemistry from the

University of California, San Diego, and brings to Flamel over twenty years experience in the

pharmaceutical and biotechnology industries.

Jeff s expertise in corporate development, market research, and intellectual property issues has

been developed both in Europe and in the U.S., remarked Stephen H. Willard, the Company s chief

executive officer. His background in these areas, together with his history of doing fundamental

research in oncology and his work in developing biotechnology, drug delivery and genomics

companies, makes him an ideal addition to the Flamel team. My colleagues and I are greatly looking

forward to Jeff s assistance in building upon Flamel s existing relationships with our

pharmaceutical and biotechnology partners and in developing new ones.

Flamel s technology platforms are ideally positioned to provide important solutions to the

pharmaceutical and biotechnology industries. These extend to efficacy and safety, but also to

important issues in drug development such as stabilization and the extension of effective half-life

without affecting bioactivity, said Mr. Vick. I am particularly pleased to be joining a company

which enjoys tremendous growth opportunities coupled with a solid financial foundation.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of

two unique polymer-based delivery technologies for medical applications. Micropump is a controlled

release and taste-masking technology for the oral administration of small molecule drugs. Flamel s

Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins

Charles Marlio, Director of Strategic Planning and Investor Relations

FRANCE: 33-4-72-78-34-34

This document contains a number of matters, particularly as related to the status of various

research projects and technology platforms, that constitute forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current

view of management with respect to future events and is subject to risks and uncertainties that

could cause actual results to differ materially from those contemplated in such forward-looking

statements. These risks include risks that products in the development stage may not achieve

scientific objectives or milestones or meet stringent regulatory requirements, uncertainties

regarding market acceptance of products in development, the impact of competitive products and

pricing, and the risks associated with Flamel s reliance on outside parties and key strategic

alliances. These and other risks are described more fully in Flamel s Annual Report on the

Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.